Last update Aug. 7, 2019
Osteoinductive proteins that cause the formation of bone tissue at the implant site.
They belong to the family of transforming growth factors TGF-beta (TGF-β) (Gálvez 2004).
Indicated as a substitute for bone graft in fusion of lumbar vertebrae and in acute tibial fractures.
Surgical administration as a local implant.
Since the last update we have not found published data on its excretion in breastmilk.
Its high molecular weight and the fact that no systemic distribution has been detected after implantation and its half-life of a few minutes (EMA 2012, p5.2) make its excretion in breastmilk very unlikely.
Zero oral bioavailability is anticipated which would impede its transfer from breastmilk into infant plasma since, due to its protein nature, it degrades in the gastrointestinal tract, and is not absorbed.
We do not have alternatives for Bone Morphogenetic Proteins (BMP).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM